Table 2.
Ongoing clinical trials with Nivolumab and other anti-PD-1 monoclonal antibodies (PDR001, JNJ-63723283, Cemiplimab) in multiple myeloma.
| Title | N | Con. | Experimental arm | Identifier Phase |
|---|---|---|---|---|
| Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma | 40 | RRMM | a) Nivolumab/Pomalidomide/ Dexamethasone b) Nivolumab/Elotuzumab/ Pomalidomide/Dexamethasone |
NCT03023527 1 put on hold (enrolment resumed) |
| An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, With or Without Pomalidomide and Dexamethasone, in Patients With Multiple Myeloma | 375 | RRMM | a) Nivolumab b) Nivolumab/Ipilimumab § c) Nivolumab/Daratumumab d) Nivolumab/Daratumumab/ Pomalidomide/Dexamethasone |
NCT01592370 1 put on hold (enrolment resumed) |
| ASCT With Nivolumab in Patients With Multiple Myeloma | 30 | NDMM* | Nivolumab | NCT03292263 1/2 |
| An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma | 70 | RRMM | a) Nivolumab/Elotuzumab b) Nivoluma/Elotuzumab/ Pomalidomide/Dexamethasone |
NCT03227432 2 |
| A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumabin Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide | 95 | RRMM | a) Elotuzumab/Pomalidamide/Dexamethasone b) Nivolumab/Elotuzumab |
NCT02612779 2 put on hold (enrolment resumed) |
| Nivolumab Combined With Daratumumab With or Without Lenalidomide | 60 | RRMM | a) Nivolumab/Daratumumab b) Nivolumab/Daratumumab/ Lenalidomide/Dexamethasone |
NCT03184194 2 |
| An Investigational Immuno-therapy Study of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma (CheckMate 602) | 406 | RRMM | a) Nivolumab/ Pomalidomide/Dexamethasone b) Pomalidomide/ Dexamethasone c) Nivolumab/Elotuzumab/ Pomalidomide/Dexamethasone |
NCT02726581 3 put on hold |
| Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma | 70 | RRMM | a) CJM112 b) PDR001/ CJM112 c) PDR001/LCL161 |
NCT03111992 1 |
| A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma | 386 | RRMM | a) Daratumumab b) JNJ-63723283/Daratumumab |
NCT03357952 1 |
| Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | 105 | RRMM | Cemiplimab/Isatuximab |
NCT03194867 1/2 |
N - estimated enrolment; Con. - condition; RRMM - relapsed or refractory multiple myeloma; NDMM - newly diagnosed multiple myeloma; mAb - monoclonal antibody; PDR001; mAb anti-PD1 - JNJ-63723283 - mAb anti-PD1; Cemiplimab - mAb anti-PD1; Ipilimumab - mAb anti-CTLA-4; Lirilumab - mAb anti-KIR; Elotuzumab - mAb anti-SLAMF7; CJM112 - mAb anti-IL-17A; LCL161 - mitochondrial-derived activator of caspases mimetic and inhibitor of apoptosis antagonists
*
NDMM who achieved partial remission, stable disease or progression disease after autologous stem cell transplantation,
§
Ipilimumab or Lirilumabb.